Evidence map›Paper›PMID 24603857›Full record

ArticlePloS one2014

Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications?

Jiahe Tian, Liping Fu, Dayi Yin, Jinming Zhang, Yingmao Chen, Ningyu An, Baixuan Xu

Abstract readComparative Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. PET/MRI: a frontier in era of complementary hybrid imaging.European journal of hybrid imaging · 2018
    Review
  3. Reproducibility and repeatability of same-day two sequential FDG PET/MR and PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2017
    Article
  4. FDG Whole-Body PET/MRI in Oncology: a Systematic Review.Nuclear medicine and molecular imaging · 2017
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. A Practical Approach to Optimize Scan Protocol for Simultaneous Whole-Body Positron Emission Tomography/Magnetic Resonance Imaging in Cancer Staging.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiahe TianDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Liping FuDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Dayi YinDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Jinming ZhangDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Yingmao ChenDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Ningyu AnDepartment of Radiology, Xiyuan, General Hospital of the Chinese People's Liberation Army, Beijing, China.
Baixuan XuDepartment of Nuclear Medicine, General Hospital of the Chinese People's Liberation Army, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe compared PET/MRI with PET/CT in terms of lesion detection and quantitative measurement to verify the feasibility of the novel integrated imaging modality for oncological applications. METHODOLOGY/PRINCIPAL

findingsIn total, 285 patients referred to our PET/CT center for oncological indications voluntarily participated in this same-day PET/CT and PET/MRI comparative study. PET/CT images were acquired and reconstructed following routine protocols, and then PET/MRI was performed at a mean time interval of 28±11 min (range 15-45 min). PET/MRI covered the body trunk with a sequence combination of transverse T1WI 3D-volumetric interpolated breath-hold, T2WI turbo spin echo with fat saturation, diffusion-weighted imaging with double b values (50 and 800 s/mm2), and simultaneous PET acquisition over 45 min/5 bed positions. The maximum standardized uptake value (SUVmax) was assessed by manually drawn regions of interest over fluorodeoxyglucose-positive lesions. Among 285 cases, 57 showed no abnormalities, and 368 lesions (278 malignant, 68 benign and 22 undetermined) were detected in 228 patients. When stand-alone modalities were evaluated, PET revealed 31 and 12 lesions missed by CT and MRI, respectively, and CT and MRI revealed 38 and 61 more lesions, respectively, than PET. Compared to CT, MRI detected 40 more lesions and missed 8. In the integrated mode, PET/CT correctly detected 6 lesions misdiagnosed by PET/MRI, but was false-negative in 30 cases that were detected by PET/MRI. The overall diagnosis did not differ between integrated PET/MRI and PET/CT. SUVmax for lesions were slightly higher from PET/MRI than PET/CT but correlated well (ρ = 0.85-0.91). CONCLUSIONS/SIGNIFICANCE: The novel integrated PET/MRI performed comparatively to PET/CT in lesion detection and quantitative measurements. PET from either scanner modality offered almost the same information despite differences in hardware. Further study is needed to explore features of integrated PET/MRI not addressed in this study.

Indexed as

AdultAgedFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasmsPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificityTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID24603857
PMCPMC3946212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.